Press Releases

BioMS Medical Receives $825,000 From Exercise of Warrants

Edmonton, Alberta, October 28, 2003 - BioMS Medical Corp (TSX:MS) today announced it has received proceeds of $825,000 from the exercise of approximately 330,000 broker warrants.

“These additional funds further strengthen our cash position as we prepare our lead product, MBP8298 for the treatment of multiple sclerosis, for a pivotal clinical trial,” said Kevin Giese, President of BioMS Medical.

This press release may contain forward-looking statements, which reflect the Corporation’s current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Corporation’s ongoing quarterly and annual reporting. Certain of the assumptions made in preparing forward-looking statements include but are not limited to the following: that dirucotide (MBP8298) will continue to demonstrate a satisfactory safety profile in ongoing and future clinical trials; and that BioMS Medical Corp. will complete the respective clinical trials within the timelines communicated in this release. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.